Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585098 | 0.84 | AR (0.52) | ARTSHRALDH1A1KDM4EUSP2 | |
| SCHEMBL15365364 | 0.84 | KDM4E (0.38) | ARCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL2428317 | 0.82 | GRM6 (0.41) | ARCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL9575173 | 0.82 | GRM6 (0.41) | ARCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL973688 | 0.80 | AR (0.49) | ARALDH1A1KDM4EUSP2 | |
| SCHEMBL152108 | 0.80 | EGLN2 (0.43) | ARCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL18299825 | 0.80 | ALDH1A1 (0.36) | ARCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL2956480 | 0.80 | ALDH1A1 (0.36) | ARCYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL29533592 | 0.80 | AR (0.40) | ARTSHRALDH1A1KDM4EUSP2 | |
| SCHEMBL27709086 | 0.80 | AR (0.40) | ARCYP3A4TSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0255956-A2 | P-Type liquid crystal composition | Sato, Hisato (JP) | 1988-02-17 | — | — | EP | claimed |
| JP-63041589-A | — | — | None | — | — | JP | disclosed |
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-05-29 | — | — | US | disclosed |
| CN-118475567-A | Heterocyclic derivative, composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-4385985-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-116724067-A | Silicone urethane (meth) acrylates and their use in 3D printing resins and coating compositions | 赢创运营有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116583546-A | Matrix resin for producing fiber composite materials | 赢创运营有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
| CN-1284063-A | Compounds | ASTRA ZENECA LTD (SE) | 2001-02-14 | — | — | CN | disclosed |
| US-5061605-A | IMPROVED SENSITIVITY TO LONG WAVELENGTHS | FUJI PHOTO FILM CO., LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
| EP-0255956-A3 | P-TYPE LIQUID CRYSTAL COMPOSITION | Sato, Hisato (JP) | 1989-06-07 | — | — | EP | disclosed |
| JP-S6341589-A | P-TYPE LIQUID CRYSTAL COMPOSITION | SATO HISATO | 1988-02-22 | — | — | JP | disclosed |
| EP-0255956-A2 | P-Type liquid crystal composition | Sato, Hisato (JP) | 1988-02-17 | — | — | EP | disclosed |
| EP-0255956-A2 | P-Type liquid crystal composition | Sato, Hisato (JP) | 1988-02-17 | — | — | EP | disclosed |
| US-4636459-A | PHOTOINITIATOR AND UNSATURATED MONOMER; PRINTING PLATES | FUJI PHOTO FILM CO., LTD. (JP) | 1987-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | AR 1/4885CYP3A4 2397/4885TSHR 838/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | AR 3751/4885CYP3A4 3113/4885TSHR 2487/4885 |
| US-20250171417-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | AR, BCKDK, CYP11B2 | AR 1/4885CYP3A4 144/4885TSHR 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.